# Milu Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/milu-labs

- Industry: Healthcare
- Headquarters: New York, US
- Website: www.milulabs.com
- Latest round: Seed (Mar 7, 2019)
- Investors on record: 1

## About

Milu Labs is a healthcare company focused on advanced diagnostic solutions for women's health, providing innovative, noninvasive tests for early detection of preterm birth and assessing future health risks through biological data analysis.Founded by Matthew Badalucco, Milu Labs operates out of New York, US. The company specializes in developing advanced diagnostic solutions tailored for women's health, with its headquarters in New York. On March 7, 2019, Milu Labs raised seed funding led by Magna Investment, marking a significant step in its growth trajectory.Milu Labs specializes in advanced diagnostic solutions specifically tailored for women's health. The company’s core offerings include sophisticated, noninvasive diagnostic tests designed to determine the likelihood of preterm birth early in pregnancy. These tests leverage innovative technologies developed in collaboration with leading researchers and clinicians, targeting unmet clinical needs in maternal health. Additionally, Milu Labs is developing two distinct diagnostic platforms that analyze a range of biological data, including the proteome, transcriptome, epigenome, and microbiome. These platforms utilize a novel approach based on the body’s natural cell signaling, enabling the generation of a predictive 'bio-fingerprint' for assessing future health risks. The company targets markets in North America and Europe, aiming to provide healthcare providers and patients with actionable insights.Milu Labs generates revenue through direct transactions with healthcare providers and institutions, centered on their diagnostic testing services. The structure of these transactions typically involves direct sales agreements with hospitals, clinics, and specialized healthcare facilities, where clients purchase diagnostic tests on a per-case basis. As part of its business model, the company may also engage in partnerships with healthcare organizations to integrate its technologies into existing healthcare frameworks. The pricing strategy includes costs associated with each individual test, reflecting the sophisticated nature of the diagnostic technologies employed. Milu Labs focuses on establishing a sustainable revenue stream by ensuring that its offerings not only fulfill clinical needs but also enhance patient care outcomes, thereby solidifying its position in the healthcare market.Milu Labs plans to enhance its product offerings by developing new diagnostic solutions, with several products slated for release in the upcoming years. The company aims to expand its footprint into new markets across Europe and North America by 2025, capitalizing on its innovative diagnostic technologies. The funding raised in March 2019 will be utilized to support these initiatives, facilitating the growth of its diagnostic platforms and enhancing operational capabilities.

## Funding rounds

- Seed, Mar 7, 2019 — Magna Investment

## Investors

- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Seed